Use of antipsychotic medicationin chemotherapy-induced nausea and vomiting

References

• Early DS. Gastrointestinal complications of chemotherapy. In: The Chemotherapy Sourcebook 3rd edition.Perry MC (Ed.), Lipincott Williams & Wilkins, Baltimore, MD, USA (2001).
   Google Scholar
• Pendergrass KB. Options in the treatment of chemotherapy-induced emesis. Cancer Practice 6,276–280 (1998).
   PubMedGoogle Scholar
• Dolgin MJ, Katz ER, McGinty K etal. Anticipatory nausea and vomiting in pediatric cancer patients. Pediatrics 75, 547–552 (1985).
   Google Scholar
• Stefanek ME, Sheidler PB, Petting JH. Anticipatory nausea and vomiting: does it remain a significant clinical problem? Cancer62, 2654–2657 (1988).
   Google Scholar
• Andrykowski MA, Jacobsen PB, Marks E etal Prevalence, predictors and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer62, 2607–2613 (1988).
   PubMedGoogle Scholar
• Greenberg DB, Kornblith AB, Herndon JE etal Quality of life for adult leukemia survivors treated on clinical trials of cancer and leukemia group B during the period 1971-1988. Cancer80, 1936–1944 (1997).
   PubMed Web of Science ®Google Scholar
• Hesketh P, Kris M, Grunberg SM etal Proposal for classifying the acute emetogenicity of cancer chemotherapy. Clin. Oncol 15,103–109 (1997).
   Web of Science ®Google Scholar
• •Provides a detailed listing of all commonly-used chemotherapeutic agents and compares their relative emetogenicity.
   Google Scholar
• American Society of Health-Systems Pharmacists. Therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am. J. Heath Syst. Phatm. 56,729–764 (1999).
   PubMedGoogle Scholar
• Homby PS. Central neurocircuitry associated with emesis. Am. J. Med. 111, 106S-112S (2001).
   Google Scholar
• •Recent review which synthesizes several decades of work in this area.
   Google Scholar
• Borison HL. Effect of ablation of medullary emetic chemoreceptor trigger zone on vomiting responses to cerebral intraventricular injection of adrenaline, apomorphine and pilocarpine in the cat. J. Physiol (lZoncL)147,172–177 (1959).
   PubMed Web of Science ®Google Scholar
• Lindstrom PA, Brizzee KR. Relief of intractable vomiting from surgical lesions in the area postrema. I Neurosurg. 19, 228–246 (1962).
   PubMedGoogle Scholar
• Harding RK, Hugenholz H, Keany M etal Discrete lesions of the area postrema abolish radiation-induced emesis in the dog. Neurosci. Lett. 53,95–100 (1985).
   PubMed Web of Science ®Google Scholar
• McCarthy LE, Borison HL. Cisplatin- induced vomiting eliminated by ablation of the area postrema in cats. Cancer 7i-eat. Rep. 68,401-404 (1984).
   Google Scholar
• Proctor JD, Athanossios N. An apomorphine-induced vomiting model for anti-emetic studies in man. J. Clin. Pharmacol 18,95–99 (1978).
   PubMedGoogle Scholar
• Stafanini E, Clement-Cornier Y. Detection of dopamine receptors in the area postrema. Eur Phatmacol. 74,257–260 (1981).
   PubMedGoogle Scholar
• Veyrat-Follet C, Farinotti R, Palmer JC. Physiology of chemotherapy-induced emesis and anti-emetic therapy. Drugs 5, 206–234 (1997).
   Google Scholar
• Ison PJ, Peroutka SJ. Neurotransmitter receptor binding studies predict anti-emetic efficacy and side effects. Cancer 7i-eat. Rep. 70,637-641 (1986).
   Google Scholar
• Gralla RJ, Itri LM, Pisko SE etal Anti- emetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl. I Med. 305,905–909 (1981).
   PubMed Web of Science ®Google Scholar
• Fortner CL, Finley RS, Grove WR. Combination of anti-emetic therapy in the control of chemotherapy-induced emesis. Drug Intel. Clin. Phatmacy19,21–24 (1985).
   Google Scholar
• Basurto C, Roila F, Tonato M et al Anti- emetic activity of high-dose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients. Am. J. Clin. Oncol 12,235–238 (1989).
   PubMedGoogle Scholar
• Mitchelson E Pharmacological aspects affecting emesis. A review (Part 1). Drugs 43,295–315 (1992).
   PubMedGoogle Scholar
• Osborne RJ, Slevin ML, Hunter RW et al Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone. Hum. Toxicol 4,617–626 (1985).
   PubMedGoogle Scholar
• Chinn HI, Wang SC. Locus of emetic action following irradiation. Proc. Soc.Exp. Biol. Med. 85,472–474 (1954).
   PubMed Web of Science ®Google Scholar
• Andrews PLR, Davis CJ, Bingham S et al. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology and plasticity. Can. J. Physiol. Pharmacol. 68, 325–345 (1990).
   PubMed Web of Science ®Google Scholar
• Leslie RA. Comparative aspects of the area postrema: fine structural considerations help to determine its function. Cell. Mol. Neurobiol. 6, 95–120 (1986).
   PubMed Web of Science ®Google Scholar
• Lindley C, Blower P. Oral serotonin Type 3-receptor agonists for prevention of
   Google Scholar
• • chemotherapy-induced emesis. Am. J. Health Syst. Pharm. 57, 1685–1697 (2000).
   Google Scholar
• Andrews PLR. 5-HT3 receptor antagonists
   Google Scholar
• Fozard JR. Neuronal 5-HT receptors in the periphery. Neurophalmacology23, 1473–1486 (1984). 24Andrews PLR, Davis CJ, Bingham S et al. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology and plasticity. Can. J. Physiol Pharmacol 68, 325–345 (1990).
   Google Scholar
• Pratt GD, Bowery NG, Kilpatrick GJ eta]. Consensus meeting agrees distribution of 5-HT3 recptors in mammalian hindbrain. 71-ends Pharmacol Sc]. 11, 135–137 (1990).
   Google Scholar
• Higgins GA, Kipatrick GJ, Bruce KT eta]. 5-HT3 receptor antagonists injected into the area postrema can inhibit cisplatin-induced emesis in the ferret. BE J. Pharmacol 97, 247–255 (1989).
   Google Scholar
• Miner WD, Sanger GJ. Inhibition of cispatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br. Phalmacol. 88, 497–499 (1986).
   Google Scholar
• Costall B, Domeney AM, Naylor RJ eta]. 5- Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology25, 959–961 (1986).
   Google Scholar
• Kris MG, Gralla RJ, Clark RA eta]. Dose- ranging evaluation of the serotonin antagonist GR-0507/75 (GR 38032F) when used as an anti-emetic in patients receiving anticancer chemotherapy. j Clin. Oncol 6,659–662 (1988).
   Google Scholar
• de Haan LD, De Mulder PH, Beex LV etal The efficacy of GR 38032F, an antagonist of 5-hydroxy-tryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting. Eur. j Cancer Clin. Oncol 24, 1383–1384 (1988).
   Google Scholar
• Leibundgut U, Lancranjan I. First results with ICS 205–930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet1(8543), 1198 (1987).
   Google Scholar
• Seynaeve C, van Liessum P, Verweij J et al GR 38032F in the prophylaxis of nausea and vomiting induced by cancer chemotherapy. Cancer Chemother. Pharmacol 23(Suppl.), 68 (1989).
   Google Scholar
• Marty M, Pouillart P, Scholl S eta]. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR38032F) with high dose metoclopramide in the control of cisplatin-induced emesis. N Engl. Med 322, 816–821 (1990). Key paper in the transition from neuroleptics to 5-HT3 antagonists as the predominant clinical agents.
   Google Scholar
• De Mulder PHM, Seynaeve C, Vermorken JB etal Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann. Intern Med. 113, 834–840 (1990).
   PubMedGoogle Scholar
• Berger AM, Clark-Snow RA. Nausea and vomiting. In: Cancer: Principles and Practice of Oncology 6th edition. Devita VT, Hellman S, Rosenberg SA (Eds), Lipincott Williams & Wilkins, Baltimore, MD, USA (2001).
   Google Scholar
• Krzakowski M, Graham E, Goedhals L etal A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Anti Cancer DITIF 9, 593–598 (1998).
   Google Scholar
• Dilly SG, Friedman C, Yocum K. Contribution of dexamethasone to anti-emetic control with granisetron is greatest in patients with high risk of emesis. Floc. Am. Soc. Clin. Oncol 13, 446 (1994).
   Google Scholar
• Laszlo J, Clark RA, Hanson DC et al Lorazepam in cancer patients treated with cisplatin: a drug having anti-emetic, amnesic and anxiolytic effects. j Clin. Oncol 3, 864–869 (1985).
   PubMed Web of Science ®Google Scholar
• Frytak S, Moertel CG, O'Fallon JR et al Delta-9-tetrahydrocannabinol as an anti-emetic for patients receiving cancer chemotherapy: a comparison with prochlorperazine and a placebo. Ann. Intern Med. 91, 825–830 (1979).
   Google Scholar
• Gralla RJ, Tyson LB, Bordin LA etal Anti- emetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat. Rep. 68, 163–172 (1984).
   Google Scholar
• Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev. 73, 229–308 (1993).
   PubMed Web of Science ®Google Scholar
• Gardner CJ, Bountra C, Bunce KT eta]. Anti-emetic activity of neurokinin receptor antagonists is mediated centrally in the ferret. BE J. Pharmacol 112 (Suppl.), 516P (1994).
   Google Scholar
• Tattersall FD, Rycroft W, Hale JJ eta]. The NK1 receptor antagonist L-754,030 and its N-phosphoryl prodrug L-758,298 inhibit acute and delayed cisplatin-induced emesis in the ferret. Proc. Am. Soc. Clin. Oncol 17, 253a (1998).
   Google Scholar
• Tattersall FD, Rycroft W, Cumberland M eta]. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298 inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropsychopharmacolagy 139, 652–663 (2000).
   Google Scholar
• Bountra C, Bunce K, Dale T etal Anti- emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994 in ferrets. Eur. j Pharmacol 249, R3—R4 (1993).
   Google Scholar
• Kris MG, Redford JE, Pizzo BA etal Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. j Natl Cancer Inst. 89, 817–818 (1997).
   PubMed Web of Science ®Google Scholar
• Navari RM, Reinhardt RR, Gralla RJ etal Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N. Engl. Med 340, 190–195 (1999).
   Google Scholar
• Hesketh PJ, Gralla RJ, Webb RT etal Randomized Phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. I Clin. Oncol 17, 338–343 (1999).
   Google Scholar
• Van Belle S, Lichinitser MR, Navari RM eta]. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer94, 3032–3041 (2002).
   Google Scholar
• Pirl WF, Roth AJ. Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psycho-oncology9, 84–87 (2000). First report of an atypical antipsychotic relieving chemotherapy-induced nausea and vomiting.
   Google Scholar
• Passik SD, Lundberg J, Kirsh KL etal A pilot exploration of the anti-emetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J. Pain Symp. Manag. 23, 526–532 (2002). First prospective study involving the use of an atypical antipsychotic to treat nausea and vomiting in cancer patients.
   Google Scholar
• Redd WH, Andrykowski MA. Behavioral intervention in cancer treatment: controlling aversion reactions to chemotherapy. j Consult. Clin. Psychology 50,1018–1029 (1982).
   PubMed Web of Science ®Google Scholar
• Morrow GR, Rosenthal SN. Models, mechanisms and management of anticipatory nausea and emesis. Oncology 53\(Suppl. 1), 4–7 (1996).
   Google Scholar
• Blasco T Anticipatory nausea and vomiting: Are psychological factors adequately investigated? BE j Clin. PTchology33,85–100 (1994).
   Google Scholar
• Aapro MS, Kirchner V, Terrey JR The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: The effect of granisetron. BE j Cancer 69, 957–960 (1994).
   Google Scholar
• Morrow GR, Roscoe JA, Kirshner JJ etal Anticipatory nausea and vomiting in the era of 5-HT3 anti-emetics. Support. Cam Cancer 6,244–247 (1998).
   Google Scholar
• Marchioro G, Azzarello G, Viviani F eta]. Hypnosis in the treatment of anticipatory nausea and vomiting in patients receiving cancer chemotherapy. Oncology59, 100–104 (2000).
   Google Scholar
• Morrow GR, Asbury R, Hammon S et al Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses and clinical psychologists. Health Rychol 11, 250–256 (1992).
   PubMed Web of Science ®Google Scholar
• Andrykowski MA. The role of anxiety in the development of anticipatory nausea in cancer chemotherapy: A review and synthesis. PTchosom. Med. 52,458–475 (1990).
   PubMed Web of Science ®Google Scholar
• Morrow GR, Hickok JT, Burish TG etal Frequency and clinical implications of delayed nausea and emesis. Am j Clin. Oncol 19,199–203 (1996).
   PubMedGoogle Scholar
• Roila F, Boschetti E, Tonato M etal Predictive factors in delayed emesis in cisplatin-treated patients and tolerability of metoclopramide or dexamethasone. Am. Clin. Oncol Cancer Clin. Ptak 14,238–242 (1991).
   PubMed Web of Science ®Google Scholar
• Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs52, 639–648 (1996).
   PubMed Web of Science ®Google Scholar
• Fredrikson M, Hurst TJ, Steineck G etal Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. Br J. Cancer 70,642–645 (1994).
   PubMed Web of Science ®Google Scholar
• The Italian Group For Anti-emetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl. I Med. 342,1554–1559 (2000).
   PubMed Web of Science ®Google Scholar
• Roila F, Ballatori E. The efficacy of cost- effectiveness of various anti-emetic agents. Cum Opin. Oncol 10,310–315 (1998).
   PubMedGoogle Scholar
• Jones AL, Lee GJ, Bosanquet N. The budgetary impact of 5-HT3 receptor antagonists in the management of chemotherapy-induce emesis. Eur. Cancer 29A, 51–56 (1993).
   Google Scholar
• •Documents the very significant rise in cost of treating chemotherapy-induced nausea and vomiting since the introduction of the 5-HT3 antagonists.
   Google Scholar
• Sanchez LA, Holdsworth M, Bartel SB. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. PharmacoEconomics 18,533–555 (2000).
   Google Scholar
• Mazzocato C, Stiefel F, Buclin T etal Psychopharmacology in supportive care of cancer: a review for the clinician. II. Neuroleptics. Support. Cam Cancer 8,89–97 (2000).
   PubMed Web of Science ®Google Scholar
• Fleishman SB, Lavin MR, Sattler M etal Anti-emetic-induced akathisia in cancer patients receiving chemotherapy. Am. Psychiatry 151,763–765 (1994).
   PubMedGoogle Scholar
• Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. j Clin. Psychiatry 59\(Suppl. 12), 17–22 (1998).
   Google Scholar
• •Good review of emerging changes in side-effect profiles.
   Google Scholar
• Casey DE. Side effect profiles of new antipsychotic agents. j Clin. Rychiatry 57\(Suppl. 11), 40–45 (1996).
   Google Scholar
• Kane JM, Honigfeld G, Singer J etal. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Rychiatry 45,789–796 (1988).
   Google Scholar
• Goldstein LE, Sporn J, Brown S etal New- onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. PTchosomatics 40,438–443 (1999).
   PubMed Web of Science ®Google Scholar
• Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Rychosomatics 39,422–430 (1988).
   Google Scholar
• Markus MM, Nomikos GG, Malmerfelt A etal Effect of chronic antipsychotic drug treatment on preprosomatostatin and preprotachykinin A mRNA levels in the prefrontal cortex, the nucleus accumbens and the caudate putamen of the rat. Brain Res. Mal Brain Res. 45,275–282 (1997).
   PubMedGoogle Scholar
• Zachrisson O, Nomikos GG, Marcus MM etal Effects of antipsychotic drugs on cholecystokinin and preprotachykinin (substance mRNA expression in the rat hippocampal formation. Eur. Neuropsychopharmacol 10,355–363 (2000).
   PubMedGoogle Scholar